Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients—a single-center retrospective study

2021 ◽  
Author(s):  
Bernard Regidor ◽  
Marissa-Skye Goldwater ◽  
Jessica Wang ◽  
Sean Bujarski ◽  
Regina Swift ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Retrospective Study ◽  
Low Dose ◽  
Single Center ◽  
Refractory Multiple Myeloma

Daratumumab therapy for relapsed or refractory multiple myeloma: a single-center retrospective study

2020 ◽  
Vol 25 (12) ◽  
pp. 2151-2157
Author(s):  
Kazutaka Sunami ◽  
Hiroyuki Murakami ◽  
Hisashi Tagashira ◽  
Hiroko Ueda ◽  
Takashi Moriyama ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Retrospective Study ◽  
Single Center ◽  
Refractory Multiple Myeloma

Pomalidomide, cyclophosphamide, and dexamethasone for relapsed/refractory multiple myeloma patients in a real-life setting: a single-center retrospective study

2019 ◽  
Vol 98 (6) ◽  
pp. 1441-1447 ◽  
Author(s):  
Sabrina Trudel ◽  
Benoît Tessoulin ◽  
Maxime Jullien ◽  
Nicolas Blin ◽  
Thomas Gastinne ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Retrospective Study ◽  
Real Life ◽  
Single Center ◽  
Refractory Multiple Myeloma ◽  
Real Life Setting

scholarly journals PB2146 SINGLE AGENT DARATUMUMAB IN VERY ADVANCED RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS: A REAL-LIFE SINGLE CENTER RETROSPECTIVE STUDY

HemaSphere ◽  
2019 ◽  
Vol 3 (S1) ◽  
pp. 965-966 ◽  
Author(s):  
M. Jullien ◽  
S. Trudel ◽  
B. Tessoulin ◽  
B. Mahé ◽  
V. Dubruille ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Retrospective Study ◽  
Single Agent ◽  
Real Life ◽  
Single Center ◽  
Refractory Multiple Myeloma

Single-agent daratumumab in very advanced relapsed and refractory multiple myeloma patients: a real-life single-center retrospective study

2019 ◽  
Vol 98 (6) ◽  
pp. 1435-1440 ◽  
Author(s):  
Maxime Jullien ◽  
Sabrina Trudel ◽  
Benoit Tessoulin ◽  
Béatrice Mahé ◽  
Viviane Dubruille ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Retrospective Study ◽  
Single Agent ◽  
Real Life ◽  
Single Center ◽  
Refractory Multiple Myeloma

Continuous low-dose dexamethasone in relapsed or refractory multiple myeloma

2000 ◽  
Vol 111 (1) ◽  
pp. 381-381 ◽  
Author(s):  
C. W. Tiplady ◽  
G. P. Summerfield
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Refractory Multiple Myeloma

Carfilzomib in Relapsed/Refractory Multiple Myeloma, Single Center Experience

2015 ◽  
Vol 15 ◽  
pp. e306-e307
Author(s):  
Y. Aydin ◽  
I. Erdogan ◽  
A. Salihoglu ◽  
T. Elverdi ◽  
F.F. Yalniz ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Single Center ◽  
Refractory Multiple Myeloma ◽  
Single Center Experience

Phase I Study of 30-Minute Infusion of Carfilzomib As Single Agent or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma

2015 ◽  
Vol 33 (7) ◽  
pp. 732-739 ◽  
Author(s):  
Kyriakos P. Papadopoulos ◽  
David S. Siegel ◽  
David H. Vesole ◽  
Peter Lee ◽  
Steven T. Rosen ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Plasma Concentration ◽  
Phase I ◽  
Phase I Study ◽  
Low Dose ◽  
Single Agent ◽  
Phase Iii ◽  
Maximum Plasma ◽  
Irreversible Inhibitor ◽  
Refractory Multiple Myeloma

Purpose Carfilzomib is an irreversible inhibitor of the constitutive proteasome and immunoproteasome. This phase I study evaluated the maximum-tolerated dose (MTD), pharmacokinetics, and pharmacodynamics of carfilzomib administered as a 30-minute intravenous (IV) infusion. Safety and efficacy of carfilzomib as a single agent or in combination with low-dose dexamethasone were assessed. Patients and Methods Patients with relapsed and/or refractory multiple myeloma (MM) were administered single-agent carfilzomib on days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. Cycle one day 1 and 2 doses were 20 mg/m2, followed thereafter by dose escalation to 36, 45, 56, or 70 mg/m2. Additionally, carfilzomib was combined with low-dose dexamethasone (40 mg/wk). Results Thirty-three patients were treated with single-agent carfilzomib. Dose-limiting toxicities in two patients at 70 mg/m2 were renal tubular necrosis and proteinuria (both grade 3). The MTD was 56 mg/m2. Nausea (51.5%), fatigue (51.5%), pyrexia (42.4%), and dyspnea and thrombocytopenia (each 39.4%) were the most common treatment-related toxicities. Overall response rate (ORR) was 50% (56-mg/m2 cohort). Increasing carfilzomib dosing from 20 to 56 mg/m2 resulted in higher area under the plasma concentration-time curve from time zero to last sampling and maximum plasma concentration exposure with short half-life (range, 0.837 to 1.21 hours) and dose-dependent inhibition of proteasome chymotrypsin-like activity. In 22 patients treated with 45 or 56 mg/m2 of carfilzomib plus low-dose dexamethasone, the ORR was 55% with a safety profile comparable to that of single-agent carfilzomib. Conclusion Carfilzomib administered as a 30-minute IV infusion at 56 mg/m2 (as single agent or with low-dose dexamethasone) was generally well tolerated and highly active in patients with relapsed and/or refractory MM. These data have provided the basis for the phase III randomized, multicenter trial ENDEAVOR.

scholarly journals A Phase 1 and 2 study of Filanesib alone and in combination with low-dose dexamethasone in relapsed/refractory multiple myeloma

Cancer ◽  
2017 ◽  
Vol 123 (23) ◽  
pp. 4617-4630 ◽  
Author(s):  
Jatin J. Shah ◽  
Jonathan L. Kaufman ◽  
Jeffrey A. Zonder ◽  
Adam D. Cohen ◽  
William I. Bensinger ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Low Dose ◽  
Phase 1 ◽  
Refractory Multiple Myeloma
Sign in / Sign up

Export Citation Format

Share Document